Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

3 Q&A interview with Jack Egelund, CEO, MedTech Bridge

28 September 2026 · By · Wire by Fusion42

Published

28 September 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

Europe

◆ Source

Read at mva.org →

◆ Verified

Fusion42 · 28 September 2026 · Fusion42 review

MedTech Bridge supports European medtech companies entering the US market by navigating its centralised FDA regulatory process and streamlined access to reimbursement and customers, providing a faster commercialisation route amid challenging and fragmented EU MDR/IVDR regulations.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Your fastest route to revenue for European medtech now runs through the US. Focus on building US regulatory and reimbursement connections this week to bypass EU delays and start sales sooner.

◆ Coverage

1 source · 28 Sep 2026

◆ Related on Wire

◆ Topics

Medtechmedtechregulatoryus-marketeuropean-unionmdr-ivdrcommercialisation